Table 2.
PCR-corrected treatment efficacy for each treatment at fixed timepoints in each shared study pooled by random effects
|
Day 28 |
Day 42 |
Day 63 |
||||
|---|---|---|---|---|---|---|
| N | % (95% CI) | N | % (95% CI) | N | % (95% CI) | |
| AL | 1168 | 96·9 (94·5–98·5) | 929 | 95·5 (92·6–97·5) | 598 | 93·6 (89·1–96·7) |
| AAP | 58 | 99·9 (98·4–100·0) | 49 | 98·9 (91·5–100·0) | 40 | 98·5 (91·4–99·9) |
| AC | 106 | 99·5 (97·4–99·9) | 73 | 98·6 (85·4–100·0) | 39 | 97·5 (71·4–100·0) |
| AS | 169 | 95·9 (88·4–99·1) | 140 | 95·6 (87·3–99·1) | 91 | 95·3 (85·7–99·2) |
| ASAQ | 811 | 99·6 (99·2–99·9) | 782 | 99·2 (98·5–99·7) | 611 | 98·8 (97·2–99·6) |
| ASMQ | 982 | 99·9 (99·6–100·0) | 948 | 99·5 (98·3–99·9) | 717 | 99·2 (97·0–99·9) |
| ASSP | 159 | 99·0 (95·4–99·9) | 120 | 99·2 (95·7–99·9) | 113 | 99·2 (95·7–99·9) |
| DP | 815 | 99·5 (98·0–99·9) | 799 | 99·4 (97·0–99·9) | 705 | 98·4 (95·6–99·6) |
| Q | 181 | 87·7 (58·2–99·3) | 164 | 86·8 (56·6–99·3) | 128 | 84·9 (51·6–99·3) |
| QC | 43 | 99·9 (97·6–100·0) | 37 | 99·9 (97·0–100·0) | 28 | 99·9 (96·3–100·0) |
Treatment success was estimated by pooling the Kaplan-Meier survival estimates in each study by random effects method. AAP=artesunate with atovaquone-proguanil. AC=artesunate with clindamycin. AL=artemether-lumefantrine. AS=artesunate monotherapy. ASAQ=artesunate-amodiaquine. ASMQ=artesunate-mefloquine. ASSP=artesunate-sulfadoxine-pyrimethamine. DP=dihydroartemisinin-piperaquine. Q=quinine monotherapy. QC=quinine with clindamycin.